Effect of EGFR antagonists gefitinib (iressa) and C225 (cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line

In Vivo

Volumn 20, Issue 6 B, 2006, Pages 791-796

  Epperly, Michael W ^a   Franicola, Darcy ^a   Zhang, Xichen ^a   Nie, Suhua ^a   Greenberger, Joel S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

EGFR antagonist; Manganese superoxide dismutase; Radiosensitization; Tumor redox balance

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; HEAD AND NECK CANCER; IN VITRO STUDY; MOUTH CARCINOMA; NONHUMAN; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TRANSGENE; TREATMENT OUTCOME;

EID: 33846081653     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Cohen EW: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659-2665, 2006.
2. Li S, Kim JS, Kim JM, Cho MJ, Yoon WH, Song KS, Yeo SG and Kim JS: Epidermal growth factor receptor as a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 65: 705-712, 2006.
3. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR and Wilson GD: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560-5567, 2005.
4. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen Z and Ferris RL: Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 24: 5897-5904, 2005.
5. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS and Nyati MK: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66: 981-990, 2006.
6. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Homer JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M and Wong KK: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. PNAS 103: 7817-7822, 2006.
7. Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HO, Abbruzzese JL and McConkey DJ: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 66: 3802-3812, 2006.
8. Luwor RB, Lu Y, Li X, Mendelsohn J and Fan Z: The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441, 2005.
9. Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ and Golub TR: Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841-2848, 2005.
10. Kassouf W, Dinney CPN, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M and Adam L: Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 65: 10524-10535, 2005.
11. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM and Posner MR: Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23: 6976-6981, 2005.
12. Siegel-Lakhai WS, Beijnen JH and Schellens JHM: Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The Oncologist 10: 579-589, 2005.
13. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar A.F, Bunn PA and Hirsch FR: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. J Clin Oncol 23: 5007-5018, 2005.
14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy pins cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
15. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha A.R, Shah JP and Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost, radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078, 2006.
16. Li X, Luwor R, Lu Y, Liang K and Fan Z: Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25: 525-535, 2006.
17. Dittmann K, Mayer C and Rodemann H-P: Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 76: 157-161, 2005.
18. Zhang X, Gureasko J, Shen K, Cole PA and Kuriyan J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149, 2006.
19. Baumann M and Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiologlcal mechanisms, preclinical and clinical results. Radiother Oncol 72: 257-266, 2004.
20. Song J and Chen C: Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology, pp. 1757-1767, 2004.
21. Posner MR: Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. The Oncologist 10: 11-19, 2005.
22. Saba NF, Khuri FR and Shin DM: Targeting the epidermal growth factor receptor trials in head and neck and lung cancer. Ontology, pp. 153, 2006.
23. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
24. Lammering G, Valerie K, Lin P-S, Hewit TH and Schmidt-Ullrich RK: Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72: 267-273, 2004.
25. Kim JJ and Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature 5: 516-523, 2005.
26. Ciccolini F, Mandl C, Holzl-Wenig G, Kehlenbach A and Hellwig A: Prospective isolation of late development multipotent precursors whose migration is prompted by EGFR. Developmental Biology 284: 112-125, 2005.
27. Olabisi OO, Mahon GM, Kostenko EV, Liu Z, Ozer HL and Whitehead IP: Bcr interacts with components of the endosomal sorting complex required for transport-1 and is required for epidermal growth factor receptor turnover. Cancer Res 66: 6250-6260, 2006.
28. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204, 2006.
29. Nelin LD, Chicoine LG, Reber KM, English BK, Young TL and Liu Y: Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am J Respir Cell Mol Biol 33: 394-401, 2005.
30. Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, van der Kogel AJ, Thames HD and Baumann M: Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76: 162-167, 2005.
31. Eicheler W, Krause M, Hessel F, Zips D and Baumann M: Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 76: 151-156, 2005.
32. Toulany M, Dittmann K, Kruger M, Baumann M and Rodemann HP: Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of P13K-AKT pathway. Radiother Oncol 76: 143-150, 2005.
33. Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M and Benhamou E: Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 24: 2873-2878, 2006.
34. Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA and Wilson JF: Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiation Oncol Biol Phys 65: 143-151, 2006.
35. Bensadoun R-J, Benezery K, Dassonville O, Mague N, Poissonnet G, Ramaioli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy P-Y, Chamorey E, Vallicioni J, Seng H, Aizieu C, Gery B, Chauvel P, Schneider M, Santini J, Demard F and Calais G: French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiation Oncol Biol Phys 64: 983-994, 2006.
36. Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case MA, Stowell S, Sammartino D, Busse PM and Haddad RI: Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiation Oncol Biol Phys 65: 1036-1044, 2006.
37. Semrau R, Mueller R-P, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentie M, Rudat V, Volling P, Schroeder M and Eckel HE: Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiation Oncol Biol Phys 64: 1308-1316, 2006.
38. Saarilahti K, Kouri M, Collan J, Hamalainen T, Atula T, Joensuu H and Tenhunen M: Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 74: 251-258, 2005.
39. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K and Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma-the University of Iowa experience. Int J Radiation Oncol Biol Phys 63: 410-421, 2005.
40. Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel JE, Murdoch-Kinch C and Eisbruch A: Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiation Oncol Biol Phys 63: 725-731, 2005.
41. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaivan AM and Harari PM: Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by Erlotinib (Tarceva). Cancer Res 65: 3328-3335, 2005.
42. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A and Hidalgo M: Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65: 3003-3011, 2005.
43. Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology 10: 1038, 2005.
44. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF and Huang SF: Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205-1215, 2006.
45. 1-mediated activation of protein tyrosine phosphatase TCPTP. Nature Cell Biology 7: 78-86, 2005.
46. Wang M, Kirk JS, Venkataraman S, Domann FE, Zhang HJ, Schafer FQ, Flanagan SW, Weydert CJ, Spitz DR, Buettner GR and Oberley LW: Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1α and vascular endothelial growth factor. Oncogene 24: 8154-8166, 2005.
47. Rosenberg A and Knox S: Radiation sensitization with redox modulators: a promising approach. Int J Radiation Oncol Biol Phys 64: 343-354, 2006.
48. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB and Park JW: Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65: 11631, 2005.
49. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L and Leyden J: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes fro the HER1/EGFR inhibitor rash management forum. The Oncologist 10: 345-356, 2005.
50. Ahmad KA, Iskandar KB, Hirpara JL, Clement MV and Pervaiz S: Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res 64: 7867-7878, 2004.
51. Kim YM, Kim KE, Koh GY, Ho Y-S and Lee K-J: Hydrogen peroxide produced by angiopoietin-1 mediates angiogenesis. Cancer Res 66: 6167-6174, 2006.
52. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Biasiak J and Skorski T: BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108: 319-327, 2006.
53. Konings AWT, Faber H, Cotteleer F, Vissink A and Coppes RP: Secondary radiation damage as the main cause for unexpected volume effects: a histopathologic study of the parotid gland. Int J Radiation Oncol Biol Plays 64: 98-105, 2006.
54. Kahn ST and Johnstone PAS: Management of xerostomia related to radiotherapy for head and neck cancer. Oncology 19: 1827-1833, 2005.
55. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen M-G and Emmanouilides C: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351: 2590-2598, 2004.
56. 18F] - misonidazole positron emission tomography - detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol 24: 2098-2104, 2006.
57. Cassatt DR, Fazenbaker CA, Bachy CM, Kifle G and McCarthy MP: Amifostine (ethyol) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Int J Radiation Oncol Biol Phys 61: 901-907, 2005.
58. Hakim SG, Kosmehl H, Lauer I, Nadrowitz R, Wedel T and Sieg P: Comparative study on the protection profile of lidocaine, Amifostine, and pilocarpin on the parotid gland during radiotherapy. Cancer Res 65: 10486, 2005.
59. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M and De Vries A: Intravenous Amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiation Oncol Biol Phys 64: 684-691, 2006.
60. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R and Strnad V: Influence of intravenous Amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2 year followup of a prospective, randomized, phase III trial. Int J Radiation Oncol Biol Phys 63: 985-990, 2005.
61. Konings AWT, Faber Hette, Vissink A and Coppes RP: Radioprotective effect of Amifostine on parotid gland functioning is region dependent. Int J Radiation Oncol Biol Phys 63: 1584-1591, 2005.
62. Epperly MW, Defilippi S, Sikora C, Gretton J, Kalend K and Greenberger JS: Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7: 1011-1018, 2000.
63. Guo HL, Seixas-Silva JA, Epperly MW, Gretton JE, Shin DM and Greenberger JS: Prevention of irradiation-induced oral cavity mucositis by plasmid/ liposome delivery of the human manganese superoxide dismutase (MnSOD) trasngene. Radiation Research 159: 361-370, 2003.
64. Guo HL, Epperly MW, Bernarding M, Nie S, Gretton J, Jefferson M and Greenberger JS: Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic lewis lung carcinomas. In Vivo 17: 13-22, 2003.
65. Epperly MW, Sikora C, Defilippi S, Gretton J, Zhan Q, Kufe DW and Greenberger JS: MnSOD inhibits irradiation-induced apoptosis by stabilization of the mitochondrial membrane against the effects of SAP kinases p38 and Jnk1 translocation. Radiation Res 157: 568-577, 2002.
66. Epperly MW, Gretton JE, Bernarding M, Nie S, Rasul B and Greenberger JS: Mitochondrial localization of copper/zinc superoxide dismutase (Cu/ ZnSOD) confers radioprotective functions in vitro and in vivo. Radiation Res 160: 568-578, 2003.
67. Epperly MW, Carpenter M, Agarwal A, Mitra P, Nie S and Greenberger JS: Intra-oral manganese superoxide dismutase plasmid liposome radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo 18: 401-410, 2004.